Shannon Kriehn
Family · Wareham, MANPI 1689126989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 303 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$989
- Pfizer$786
- AstraZeneca$673
- Lilly USA, LLC$599
- Novo Nordisk$518
- Indivior Inc.$387
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,546100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $989 |
| Pfizer | 58 | $786 |
| AstraZeneca(2 entities) | 20 | $673 |
| Lilly USA, LLC | 23 | $599 |
| Novo Nordisk | 27 | $518 |
| Indivior Inc. | 17 | $387 |
| Amgen | 9 | $242 |
| Sanofi-aventis U.S. LLC | 3 | $205 |
| Nestle Healthcare Nutrition Inc. | 10 | $189 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Vanda Pharmaceuticals Inc. | 8 | $156 |
| Biohaven Pharmaceuticals, Inc. | 10 | $135 |
| Gilead | 1 | $130 |
| Alkermes, Inc. | 3 | $128 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $120 |
| Hologic Sales And Service, LLC | 1 | $101 |
| Exact Sciences | 4 | $97 |
| Johnson & Johnson | 4 | $83 |
| Abbott | 4 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Merck | 4 | $72 |
| Lundbeck LLC | 4 | $71 |
| Lucid Diagnostics Inc. | 4 | $70 |
| Novartis | 2 | $44 |
| Sage Therapeutics, LLC | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $33 |
| Vertex | 1 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Therapeuticsmd, Inc. | 2 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,546 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $47,054 |
| EliquisApixaban | 38 | $29,691 |
| XareltoRivaroxaban | 20 | $18,645 |
| MounjaroTirzepatide | 13 | $13,292 |
| LinzessLinaclotide | 14 | $12,641 |
| OxycontinOxycodone Hcl | 14 | $10,375 |
| JardianceEmpagliflozin | 13 | $6,986 |
| Bupropion XlBupropion Hcl | 26 | $3,629 |
| Oxycodone Hcl | 168 | $2,375 |
| Varenicline Tartrate | 11 | $2,225 |
| Gabapentin | 145 | $2,107 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,782 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $1,754 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,480 |
| Omeprazole | 93 | $1,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $518 | $47,05449 claims |
| PfizerEliquis | $786 | $29,69138 claims |
| Johnson & JohnsonXarelto | $83 | $18,64520 claims |
| Lilly USA, LLCMounjaro | $599 | $13,29213 claims |
| AbbVieLinzess | $989 | $12,64114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Wareham
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
- Marissa CasilloFoxborough$31K
- Rochelle NazarianDanvers$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.